Guangdong Transtek Medical Electronics Co Ltd

Lifesense Medical disclosed its 2026 semi-annual report. In the first half, it achieved operating revenue of 534 million yuan, up 2.51% year on year. Net profit attributable to shareholders of the listed company was 60.04 million yuan, up 41.96% year on year. Basic earnings per share were 0.2748 yuan. The company plans to distribute a cash dividend of 1.3 yuan per 10 shares, tax included.

Lifesense Medical announced plans to distribute a cash dividend of 1.3 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 28.46 million yuan, accounting for 47.40% of net profit attributable to the parent company. In the first half of 2026, Lifesense Medical achieved revenue of 534 million yuan and net profit attributable to the parent company of 60.04 million yuan.

Guangdong Lifesense Medical Electronics announced that the change application for its electronic blood pressure monitor’s CE conformity certificate has been approved. This change adds four models—BBY31-BT, BBY31, BBY36-BT, and BBY36—to the original certificate’s product model list. The product consists of a main unit and a cuff, suitable for arm circumferences of 22 to 45 centimeters, and is intended for adults to measure blood pressure and pulse rate. The newly added models feature suspected atrial fibrillation detection, which identifies possible atrial fibrillation episodes by analyzing pulse pressure waveform data collected during measurement and alerts the user. This function is for preliminary screening only and is not intended for diagnosis. The company stated that this change is conducive to promoting product diversification and enhancing market expansion capabilities, but actual sales will depend on future marketing effectiveness, and the impact on future performance cannot be predicted at this time.